vimarsana.com
Home
Live Updates
Moderna, Inc.: 90-Day Analysis Shows Modernas Omicron BA.1-Targeting Bivalent Vaccine, mRNA-1273.214, Demonstrates Superior Antibody Response as Fourth Booster Compared to Spikevax Prototype Booster : vimarsana.com
Moderna, Inc.: 90-Day Analysis Shows Moderna's Omicron BA.1-Targeting Bivalent Vaccine, mRNA-1273.214, Demonstrates Superior Antibody Response as Fourth Booster Compared to Spikevax Prototype Booster
Data indicate durable immune response from bivalent booster after three months of follow-upmRNA-1273.214 also demonstrated potent response to Omicron BA.2.75CAMBRIDGE, MA / ACCESSWIRE / October 19, 2022
Related Keywords
Cambridge ,
Cambridgeshire ,
United Kingdom ,
Elise Meyer ,
Lavina Talukdar ,
Exchange Commission ,
Corporate Communications ,
Moderna Inc ,
Nasdaq ,
Chief Executive Officer ,
Emergency Use Authorization ,
Coronavirus Disease ,
Vaccine Adverse Event Reporting System ,
Fact Sheets ,
Healthcare Providers Administering Vaccine ,
Vaccine Providers ,
Full Prescribing Information ,
Private Securities Litigation Reform Act ,
Annual Report ,
Quarterly Report ,
Vice President ,
Moderna ,
Analysis ,
Shows ,
Micron ,
Targeting ,
Bivalent ,
Vaccine ,
Rna ,
273 ,
Emonstrates ,
Superior ,
Ntibody ,
Response ,
Fourth ,
Rooster ,
Ompared ,
Spikevax ,
Prototype ,
vimarsana.com © 2020. All Rights Reserved.